ClinicalTrials.gg
RecruitingNCT06001645PIE-ARDSUpdated Aug 12, 2025

Laboratory Biomarkers and Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS)

An observational study in Acute Respiratory Distress Syndrome and Barotrauma, sponsored by Università Vita-Salute San Raffaele. Recruiting at 4 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Università Vita-Salute San Raffaele · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Respiratory Distress Syndrome with a site in Italy — 21 open to participants now, 24 under way, 2 of them phase 3. Respiratory Distress Syndrome · Italy.

Planned enrollment
20th of 39
110 · median 110
Started
2023
with 7 others
Observational
40 of 91
9 open now
Primary completion
2027-04
later than 16 of 23 live
Registered
81st of 91
by date
Lead sponsor
3 of 91
Università Vita-Salute San Raffaele

Among the 91 studies in Respiratory Distress Syndrome with a site in Italy, this one is the 20th largest by planned enrollment of the 39 observational ones that give a count, is one of 8 that started in 2023, is one of 40 observational ones, reaches primary completion later than 16 of the 23 other live ones, and was the 81st registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

21 of the 91 studies in Respiratory Distress Syndrome with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Respiratory Distress Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Barotrauma (pneumothorax, pneumomediastinum) is a well-described complication of Acute Respiratory Distress Syndrome (ARDS), especially in patients with coronavirus disease 2019 (COVID-19) (16.1% in COVID-19, and about 6% in non-COVID-19 ARDS). Macklin effect was recently discovered by our group as an accurate radiological predictor of barotrauma in COVID-19 ARDS; the Investigators also found that density histograms automatically extracted from chest CT images provide a reliable insight into lung composition

. Since lung frailty is a major issue also in non-COVID-19 ARDS, the Investigators want to confirm the predictive role of Macklin effect also in this setting. In addition, the Investigators aim to explore inflammatory profiling to decipher different biological aspects of the same clinical issue. Finally, the Investigators want to develop a specific management algorithm for patients diagnosed, according to our findings, with a specific ARDS sub phenotype characterized by increased lung frailty

Read the detailed description

Barotrauma occurs frequently in acute respiratory distress syndrome (ARDS), and has a difficult, non-standardized management. Unfortunately, mortality rates remain high (> 60% in COVID-19 ARDS, around 46% in non-COVID-19 ARDS). Interestingly, data from COVID-19 patients suggested that barotrauma may occur also in spontaneously breathing patients with ARDS. Accordingly, frailty of lung parenchyma represents a major issue in ARDS. Protective mechanical ventilation (i.e. ventilation with low tidal volume and low airway pressures) remains a cornerstone of supportive management of ARDS. Unfortunately, mechanical ventilation may worsen pulmonary damage (ventilator-induced lung injury) and, in high-risk patients, may induce barotrauma even when ventilator settings are maintained within the "safe" limit of protective ARDS. Early identification of high-risk features could therefore allow clinicians to individualize management of high-risk patients, by tailoring respiratory support and potentially select candidates for advanced support (i.e. extracorporeal membrane oxygenation) before development of overt barotrauma.

Macklin effect is a well-described radiological sign originally intended to differentiate between "peripheral" (distal airway rupture, "respiratory" barotrauma) and "central" (lesion to large airways/esophaegal injury) causes of air leakage in the mediastinum. However, the Investigators recently identified Macklin effect as a strong radiological predictor of barotrauma development in mechanically ventilated COVID-19 ARDS patients (sensitivity: 89.2%; specificity: 95.6%). In our cohort, radiologically-detected Macklin effect was identified 8-12 days before development of pneumomediastinum/pneumothorax. These preliminary results have been confirmed in a subsequent multicenter study (sample size 697 patients; sensitivity: 100%; specificity: 99.8%).

Furthermore, preliminary data suggest that early application of awake veno/venous extracorporeal membrane oxygenation (ECMO) before invasive mechanical ventilation in COVID-19 patients with severe ARDS and at high-risk for barotrauma (defined as presence of Macklin effect on chest CT imaging) might result in no barotrauma events with a low intubation rate.

Concurrently, a hyper inflammatory sub phenotype has been associated with overall worse outcome both in terms of mortality and ventilator-free days in ARDS. Moreover, the occurrence of lung injury during mechanical ventilation has been proven to be significantly related to the recruitment of mast cells via CXCL10/CXCR3 signaling .

In this view, confirmation of Macklin effect predictive role and identification of further, novel laboratory biomarkers could provide instruments for early risk stratification in ARDS patients.

Taken together, i) quantitative imaging analysis and ii) systemic inflammatory profiling could decipher different biological aspects of the same clinical issue, possibly laying foundation for the definition of a multimodality signature of lung frailty in ARDS patients..

Accordingly, the driving hypotheses of this retrospective/prospective study is that identification of a novel ARDS sub phenotype characterized, irrespective of the underlying etiology, by increased lung frailty could substantially improve the poor prognosis routinely associated with this condition, possibly being a landmark for personalized management strategies.

To further validate the role of Macklin effect, the Investigators will:

  • evaluate the accuracy of Macklin effect in a retrospective cohort of 350 ARDS patients (COVID-19 and non-COVID-19)
  • identify, throughout densitometry, machine learning and artificial intelligence-based approaches, novel imaging biomarkers characteristics of higher lung frailty in the same cohort.

In the main prospective study, the Investigators will:

  • analyse the following biomarkers in the serum and bronchoalveolar lavage fluid of 100 ARDS patients prospectively enrolled: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10).
  • Develop a specific management algorithm for ARDS patients at high risk for barotrauma by collecting clinical and outcome data from 10 ARDS patients receiving unconventional management (e.g. awake ECMO, ultraprotective ventilation, etc)
03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Barotrauma

Keywords

  • Acute Respiratory Distress Syndrome
  • Mechanical Ventilation
  • Intensive Care
  • Respiratory Failure
  • Pneumothorax
  • Macklin effect
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ARDS diagnosis will be enrolled. With the exception of blood and BAL samples collection, all patients enrolled in the prospective cohort will follow their normal course of diagnosis/treatment without any further requirements for the scope of this study other than those provided in the normal management of patients with this condition. Furthermore, any decision regarding drug or procedure will be made by the physician based on her/his clinical judgment, independently from the decision to include the patient in this study. No follow-up medical and/or imaging examinations/laboratory analysis after hospital discharge are needed by the present study design.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical and radiological signs of ARDS, according to Berlin criteria, requiring ICU admission;
  • Obtain duly signed
  • Availability of at least one chest CT scan during hospital stay

Exclusion criteria

Exclusion Criteria:

  • Poor quality imaging (because of motion/respiratory artefacts).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Acute Respiratory Distress Syndrome

    Patients with ARDS requiring or not requiring invasive ventilation

    Diagnostic Test: Blood and bronchoalveolar fluid collection and analysis · Diagnostic Test: Chest CT scan

Interventions

  • Diagnostic testBlood and bronchoalveolar fluid collection and analysis

    Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.

  • Diagnostic testChest CT scan

    Computed Tomography Scan per normal clinical practice

06

What researchers measure

Primary outcomes

  1. Rate of clinically relevant barotrauma

    Barotrauma is diagnosed only in the case of clear radiological evidence (free air at chest X-ray and/or chest CT scan). Rate of barotrauma will be compared between patients with an hyperinflammatory pattern as compared with control.

    Time frame: 30 days or until hospital discharge. Specifically, from date of basal CT scan until the date of first radiologically documented barotrauma

07

Study locations

1 of 4 sites recruiting
08

References and documents

Publications

  • Murayama S, Gibo S. Spontaneous pneumomediastinum and Macklin effect: Overview and appearance on computed tomography. World J Radiol. 2014 Nov 28;6(11):850-4. doi: 10.4329/wjr.v6.i11.850. PubMed 25431639 ↗
  • Palumbo D, Zangrillo A, Belletti A, Guazzarotti G, Calvi MR, Guzzo F, Pennella R, Monti G, Gritti C, Marmiere M, Rocchi M, Colombo S, Valsecchi D, Scandroglio AM, Dagna L, Rovere-Querini P, Tresoldi M, Landoni G, De Cobelli F; COVID-BioB Study Group. A radiological predictor for pneumomediastinum/pneumothorax in COVID-19 ARDS patients. J Crit Care. 2021 Dec;66:14-19. doi: 10.1016/j.jcrc.2021.07.022. Epub 2021 Aug 12. PubMed 34392131 ↗
  • Belletti A, Pallanch O, Bonizzoni MA, Guidi L, De Cobelli F, Landoni G, Zangrillo A, De Bonis M, Palumbo D. Clinical use of Macklin-like radiological sign (Macklin effect): A systematic review. Respir Med. 2023 Apr-May;210:107178. doi: 10.1016/j.rmed.2023.107178. Epub 2023 Feb 28. PubMed 36863617 ↗
  • Paternoster G, Bertini P, Belletti A, Landoni G, Gallotta S, Palumbo D, Isirdi A, Guarracino F. Venovenous Extracorporeal Membrane Oxygenation in Awake Non-Intubated Patients With COVID-19 ARDS at High Risk for Barotrauma. J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt B):2975-2982. doi: 10.1053/j.jvca.2022.03.011. Epub 2022 Mar 17. PubMed 35537972 ↗
  • Maccarrone V, Liou C, D'souza B, Salvatore MM, Leb J, Belletti A, Palumbo D, Landoni G, Capaccione KM. The Macklin effect closely correlates with pneumomediastinum in acutely ill intubated patients with COVID-19 infection. Clin Imaging. 2023 May;97:50-54. doi: 10.1016/j.clinimag.2023.03.003. Epub 2023 Mar 4. PubMed 36889115 ↗
  • Guarracino F, Baldassarri R, Brizzi G, Isirdi A, Landoni G, Marmiere M, Belletti A. Awake Venovenous Extracorporeal Membrane Oxygenation in the Intensive Care Unit: Challenges and Emerging Concepts. J Cardiothorac Vasc Anesth. 2025 Apr;39(4):1004-1014. doi: 10.1053/j.jvca.2024.12.045. Epub 2025 Jan 9. PubMed 39843275 ↗
  • Belletti A, D'Andria Ursoleo J, Piazza E, Mongardini E, Paternoster G, Guarracino F, Palumbo D, Monti G, Marmiere M, Calabro MG, Landoni G, Zangrillo A. Extracorporeal membrane oxygenation for prevention of barotrauma in patients with respiratory failure: A scoping review. Artif Organs. 2025 Feb;49(2):183-195. doi: 10.1111/aor.14864. Epub 2024 Sep 21. PubMed 39305092 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Apr 2027, 41 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 41 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 21, 2023
StartActual
Nov 27, 2023
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06001645
Lead sponsor
Università Vita-Salute San Raffaele
Responsible party
Giovanni Landoni (Full Professor, Università Vita-Salute San Raffaele) — Principal investigator
First posted
Aug 21, 2023
Start date
Nov 27, 2023
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion